DRUGNasdaqPharmaceutical PreparationsFiscal year ends September 30
BRIGHT MINDS BIOSCIENCES INC.
Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 40-F on Dec 23, 2025
$53.82+2.52 (+4.91%)
Close on Oct 19, 2026
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
9M of 8M shares
Institutional holders
100
20 new, 12 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $9.79M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Chen Bihua | 950,000 | 9.71% | 13G (passive) amendment | Apr 28, 2026 |
| Bihua Chen | 900,000 | 9.17% | 13G (passive) amendment | Jun 30, 2026 |
| Vivo Opportunity, LLC | 504,645 | 5.20% | 13G (passive) amendment | Mar 31, 2026 |
| Vestal Point Capital, LP | 492,319 | 5.00% | 13G (passive) | Mar 31, 2026 |
| Vivo Opportunity Fund Holdings, L.P. | 454,184 | 6.40% | 13G (passive) | Sep 30, 2025 |
| Perceptive Life Sciences Master Fund, Ltd. | 444,649 | 6.30% | 13G (passive) amendment | Mar 31, 2025 |
| Adage Capital Management, L.P. | 395,743 | 5.58% | 13G (passive) | Sep 30, 2025 |
| Ian McDonald | 1,396,665 | 13.70% | 13D (active) amendment | Nov 4, 2024 |
| Janus Henderson Group PLC | 1,284,324 | 13.10% | 13G (passive) amendment | Mar 31, 2026 |
| Cormorant Asset Management, LP | 1,059,331 | 10.88% | 13G (passive) amendment | Jan 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DRUG | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 1,349,107 | 17.67% | $94.82M | New | 0.04% |
| Cormorant Asset Management, LP | 900,000 | 11.79% | $63.18M | −159,331 | 3.24% |
| BlackRock, Inc. | 686,184 | 8.99% | $48.17M | +64,251 | 0.00% |
| Vivo Capital, LLC | 557,172 | 7.30% | $39.11M | – | 3.57% |
| Vestal Point Capital, LP | 545,000 | 7.14% | $38.26M | +52,681 | 0.89% |
| Braidwell LP | 483,822 | 6.34% | $33.96M | −55,886 | 1.26% |
| Driehaus Capital Management LLC | 433,377 | 5.68% | $30.42M | +862 | 0.18% |
| Balyasny Asset Management L.P. | 345,053 | 4.52% | $24.22M | +47,895 | 0.03% |
| Adage Capital Partners Gp, L.L.C. | 335,000 | 4.39% | $23.52M | −160,743 | 0.03% |
| Point72 Asset Management, L.P. | 327,416 | 4.29% | $22.98M | New | 0.03% |
| Deerfield Management Company, L.P. (Series C) | 283,000 | 3.71% | $19.87M | – | 0.21% |
| Ra Capital Management, L.P. | 265,000 | 3.47% | $18.60M | – | 0.16% |
| Parkman Healthcare Partners LLC | 205,053 | 2.69% | $14.39M | +164,955 | 1.47% |
| Mpm Bioimpact LLC | 202,114 | 2.65% | $14.19M | −10,061 | 0.87% |
| Wellington Management Group Llp | 171,315 | 2.24% | $12.03M | +34,638 | 0.00% |
| Goldman Sachs Group Inc | 133,689 | 1.75% | $9.38M | +59,320 | 0.00% |
| Eventide Asset Management, LLC | 130,013 | 1.70% | $9.13M | – | 0.12% |
| State Street Corp | 122,178 | 1.60% | $8.58M | +13,939 | 0.00% |
| Seven Grand Managers, LLC | 120,000 | 1.57% | $8.42M | – | 0.34% |
| Great Point Partners LLC | 109,603 | 1.44% | $7.69M | −110,397 | 1.45% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 100 | 9M | 100.0% | 20 / 47 | 17 / 12 | 3M | 1M |
| Q1 2026 | 94 | 9M | 100.0% | 29 / 45 | 15 / 7 | 3M | 0M |
| Q4 2025 | 74 | 7M | 86.3% | 17 / 27 | 20 / 7 | 1M | 1M |
| Q3 2025 | 64 | 6M | 79.2% | 18 / 22 | 13 / 1 | 1M | 0M |
| Q2 2025 | 47 | 5M | 68.6% | 22 / 7 | 9 / 9 | 0M | 0M |
| Q1 2025 | 34 | 5M | 68.3% | 10 / 10 | 8 / 7 | 1M | 1M |
| Q4 2024 | 31 | 5M | 64.1% | 26 / 2 | 2 / 1 | 5M | 0M |
| Q3 2024 | 6 | 0M | 2.5% | 2 / 2 | 1 / 1 | 0M | 0M |
| Q2 2024 | 6 | 0M | 2.6% | 0 / 1 | 2 / 1 | 0M | 0M |
| Q1 2024 | 7 | 0M | 2.8% | 3 / 1 | 1 / 4 | 0M | 0M |
| Q4 2023 | 8 | 0M | 3.0% | 2 / 3 | 1 / 0 | 0M | 0M |
| Q3 2023 | 6 | 0M | 2.5% | 6 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of DRUG | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Russell 2000 ETF | 194,417 | 2.55% | $13.65M | 0.02% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 130,013 | 1.70% | $9.13M | 0.51% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 95,655 | 1.25% | $8.42M | 0.14% | May 29, 2026 |
| Fidelity Small Cap Index Fund | 81,231 | 1.06% | $5.95M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 69,591 | 0.91% | $4.89M | 0.03% | Jun 30, 2026 |
| Driehaus Micro Cap Growth Fund | 41,568 | 0.54% | $2.92M | 0.49% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 35,879 | 0.47% | $3.16M | 0.02% | May 31, 2026 |
| Vanguard U.S. Momentum Factor ETF | 28,882 | 0.38% | $2.54M | 0.14% | May 31, 2026 |
| iShares Micro-Cap ETF | 24,919 | 0.33% | $1.75M | 0.12% | Jun 30, 2026 |
| AdvisorShares Psychedelics ETF | 24,274 | 0.32% | $1.70M | 3.84% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 22,267 | 0.29% | $1.56M | 0.04% | Jun 30, 2026 |
| Adara Smaller Companies Fund | 20,238 | 0.27% | $1.78M | 0.22% | May 31, 2026 |
| Goldman Sachs Small Cap Equity Insights Fund | 18,815 | 0.25% | $1.38M | 0.14% | Jul 31, 2026 |
| Schwab Small-Cap Index Fund | 18,032 | 0.24% | $1.32M | 0.02% | Jul 31, 2026 |
| Master Small Cap Index Series | 13,852 | 0.18% | $972.41K | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Bihua Chen | – | 452,409 | 5.92% | Apr 30, 2026 |
| Cormorant Global Healthcare Master Fund, LP | – | 864,743 | 11.32% | Apr 30, 2026 |
| Cormorant Asset Management, LP | – | 950,000 | 12.44% | Apr 30, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP – | Apr 28, 2026 | Sale | −109,331 | $89.50 | $9.79M | 950,000 |
| Cormorant Asset Management, LP 10% owner | Nov 4, 2024 | Buy | +184,331 | $21.70 | $4.00M | 1,059,331 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 16, 2024 | Buy | +39,743 | $23.22 | $922.83K | 864,743 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 16, 2024 | Buy | +3,107 | $25.22 | $78.36K | 875,000 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 16, 2024 | Buy | +7,150 | $24.03 | $171.81K | 871,893 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 15, 2024 | Buy | +4,609 | $12.35 | $56.92K | 825,000 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 15, 2024 | Buy | +19,169 | $11.72 | $224.66K | 820,391 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 15, 2024 | Buy | +2,700 | $9.26 | $25.00K | 801,222 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 15, 2024 | Buy | +8,900 | $7.31 | $65.06K | 795,922 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 15, 2024 | Buy | +33,343 | $6.42 | $214.06K | 787,022 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 15, 2024 | Buy | +63,173 | $5.92 | $373.98K | 753,679 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 15, 2024 | Buy | +238,097 | $4.53 | $1.08M | 690,506 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Oct 15, 2024 | Buy | +2,600 | $8.80 | $22.88K | 798,522 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.